K. A. Baker and M. E. Ryan, What's new in diagnosis, treatment, and prevention?, Postgrad Med, vol.106, issue.7, pp.107-115, 1999.

H. Nair, D. J. Nokes, and B. D. Gessner, Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis, Lancet, vol.375, issue.9725, pp.1545-1555, 2010.

L. S. Eiland, Respiratory syncytial virus: diagnosis, treatment and prevention, Pediatric Pharmacol Ther, vol.14, issue.2, pp.75-85, 2009.

N. Lee, G. C. Lui, and K. T. Wong, High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections, Clin Infect Dis, vol.57, issue.8, pp.1069-1077, 2013.

P. L. Collins and J. A. Melero, Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years, Virus Res, vol.162, issue.1-2, pp.80-99, 2011.
DOI : 10.1016/j.virusres.2011.09.020

URL : http://europepmc.org/articles/pmc3221877?pdf=render

M. G. Cusi, B. Martorelli, D. Genova, and G. , Age related changes in T cell mediated immune response and effector memory to respiratory syncytial virus (RSV) in healthy subjects, Immun Ageing, vol.7, p.14, 2010.

L. Broadbent, H. Groves, and M. D. Shields, Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. Influenza Other Respir Viruses, vol.9, pp.169-178, 2015.

R. Garg, L. Latimer, and E. Simko, Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation, J Gen Virol, vol.95, issue.2, pp.301-306, 2014.

R. Garg, L. Latimer, and V. Gerdts, The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies, Vaccine, vol.33, issue.11, pp.1338-1344, 2015.

X. Zhan, J. L. Hurwitz, and S. Krishnamurthy, Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B, Vaccine, vol.25, issue.52, pp.8782-8793, 2007.

B. G. Jones, R. E. Sealy, and R. Rudraraju, Sendai virus-based RSV vaccine protects African green monkeys from RSV infection, Vaccine, vol.30, issue.5, pp.959-968, 2012.
DOI : 10.1016/j.vaccine.2011.11.046

URL : http://europepmc.org/articles/pmc3256274?pdf=render

B. G. Jones, R. E. Sealy, and S. L. Surman, Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model, Vaccine, vol.32, issue.26, pp.3264-3273, 2014.

Y. N. Lee, H. S. Hwang, and M. C. Kim, Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease, Virology, vol.476, pp.217-225, 2015.

W. H. Alwan, W. J. Kozlowska, and P. J. Openshaw, Distinct types of lung disease caused by functional subsets of antiviral T cells, J Exp Med, vol.179, issue.1, pp.81-89, 1994.

I. S. Cheon, B. S. Shim, and S. M. Park, Development of safe and effective RSV vaccine by modified CD4 epitope in G protein core fragment (Gcf), PLoS One, vol.9, issue.4, p.94269, 2014.

T. Chirkova, S. Boyoglu-barnum, and K. A. Gaston, Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses, J Virol, vol.87, issue.24, pp.13466-13479, 2013.
DOI : 10.1128/jvi.01741-13

URL : https://jvi.asm.org/content/jvi/87/24/13466.full.pdf

P. A. Jorquera, Y. Choi, and K. E. Oakley, Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease, Plos One, vol.8, issue.9, p.74905, 2013.
DOI : 10.1371/journal.pone.0074905

URL : https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0074905&type=printable

X. Roux, C. Dubuquoy, and G. Durand, Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus, PloS one, vol.3, issue.3, p.1766, 2008.
DOI : 10.1371/journal.pone.0001766

URL : https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0001766&type=printable

A. Sawada, K. Komase, and T. Nakayama, AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats, Vaccine, vol.29, issue.7, pp.1481-1490, 2011.

Y. Yamaji and T. Nakayama, Recombinant measles viruses expressing respiratory syncytial virus proteins induced virus-specific CTL responses in cotton rats, Vaccine, vol.32, issue.35, pp.4529-4536, 2014.
DOI : 10.1016/j.vaccine.2014.06.024

, * Comparison of different recombinant measles virus expressing F, G, N and M2-1 protein and its effects on cellular and humoral response

J. A. Espinoza, S. M. Bueno, and C. A. Riedel, Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design, Immunology, vol.143, issue.1, pp.1-12, 2014.

M. Dennehy, W. Bourn, and D. Steele, Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus

A. Rivera, vaccine. Vaccine, vol.25, issue.18, pp.3646-3657, 2007.

G. J. Fennelly, J. L. Flynn, T. Meulen, and V. , Recombinant bacille CalmetteGuerin priming against measles, J Infect Dis, vol.172, issue.3, pp.698-705, 1995.
DOI : 10.1093/infdis/172.3.698

S. M. Bueno, P. A. Gonzalez, and K. M. Cautivo, Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG, Proc Natl Acad Sci, vol.105, issue.52, pp.20822-20827, 2008.
DOI : 10.1073/pnas.0806244105

URL : http://www.pnas.org/content/105/52/20822.full.pdf

K. M. Cautivo, S. M. Bueno, and C. M. Cortes, Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guerin promotes virus clearance and protects from infection, J Immunol, vol.185, issue.12, pp.7633-7645, 2010.
DOI : 10.4049/jimmunol.0903452

URL : http://www.jimmunol.org/content/185/12/7633.full.pdf

G. T. Jennings and M. F. Bachmann, The coming of age of virus-like particle vaccines, Biol Chem, vol.389, issue.5, pp.521-536, 2008.

T. G. Morrison and E. E. Walsh, Subunit and virus-like particle vaccine approaches for respiratory syncytial virus, Curr Top Microbiol Immunol, vol.372, pp.285-306, 2013.
DOI : 10.1007/978-3-642-38919-1_14

F. S. Quan, Y. Kim, and S. Lee, Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice, J Infect Dis, vol.204, issue.7, pp.987-995, 2011.
DOI : 10.1093/infdis/jir474

URL : https://academic.oup.com/jid/article-pdf/204/7/987/18065938/jir474.pdf

S. Lee, F. S. Quan, and Y. Kwon, Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins
DOI : 10.1016/j.antiviral.2014.09.005

URL : http://europepmc.org/articles/pmc4252885?pdf=render

, Antiviral Res, vol.111, pp.129-135, 2014.

L. W. Mcginnes, K. A. Gravel, and R. W. Finberg, Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins, J Virol, vol.85, issue.1, pp.366-377, 2011.

M. R. Schmidt, L. W. Mcginnes, and S. A. Kenward, Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains, J Virol, vol.86, issue.21, pp.11654-11662, 2012.
DOI : 10.1128/jvi.01510-12

URL : https://jvi.asm.org/content/jvi/86/21/11654.full.pdf

J. Wilschut, Influenza vaccines: the virosome concept, Immunol Lett, vol.122, issue.2, pp.118-121, 2009.

C. Moser, M. Muller, and M. D. Kaeser, Influenza virosomes as vaccine adjuvant and carrier system, Exp Rev Vacc, vol.12, issue.7, pp.779-791, 2013.

M. Shafique, T. Meijerhof, and J. Wilschut, Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses, PLoS One, vol.8, issue.4, p.61287, 2013.

T. Kamphuis, T. Meijerhof, and T. Stegmann, Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice, PLoS One, vol.7, issue.5, p.36812, 2012.

T. Kamphuis, T. Stegmann, and T. Meijerhof, A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats. Influenza Other Respir Viruses, vol.7, pp.1227-1236, 2013.

C. Luongo, C. C. Winter, and P. L. Collins, Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature, J Virol, vol.87, issue.4, pp.1985-1996, 2013.

J. Meng, S. Lee, and A. L. Hotard, Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes, mBio, vol.5, issue.5, pp.1704-1718, 2014.

M. S. Lo, R. M. Brazas, and M. J. Holtzman, Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness, J Virol, vol.79, issue.14, pp.9315-9319, 2005.

R. A. Karron, P. F. Wright, and R. B. Belshe, Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants, J Infect Dis, vol.191, issue.7, pp.1093-1104, 2005.

J. H. Schickli, J. Kaur, and R. S. Tang, Nonclinical phenotypic and genotypic analyses of a Phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/ 404/1030DeltaSH) at permissive and nonpermissive temperatures, Virus Res, vol.169, issue.1, pp.38-47, 2012.

E. Malkin, R. Yogev, and N. Abughali, Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSVseronegative children 5 to 24 months of age, PLoS One, vol.8, issue.10, p.77104, 2013.

F. M. Munoz, Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?, Curr Opin Infect Dis, vol.28, issue.3, pp.221-224, 2015.

P. Kaaijk, W. Luytjes, and N. Y. Rots, Vaccination against RSV: is maternal vaccination a good alternative to other approaches?, Hum Vacc Immunother, vol.9, issue.6, pp.1263-1267, 2013.

, * Animal study of maternal immunization against hRSV

Y. M. Kwon, H. S. Hwang, and J. S. Lee, Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease, Antiviral Res, vol.104, pp.1-6, 2014.

L. G. Stensballe, H. Ravn, and K. Kristensen, Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus, J Pediatr, vol.154, issue.2, pp.296-298, 2009.

B. R. Murphy, D. W. Alling, and M. H. Snyder, Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection, J Clin Microbiol, vol.24, issue.5, pp.894-898, 1986.

B. R. Murphy, R. A. Olmsted, and P. L. Collins, Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses, J Virol, vol.62, issue.10, pp.3907-3910, 1988.

J. J. Shinoff, K. L. O'brien, and B. Thumar, Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus, J Infect Dis, vol.198, issue.7, pp.1007-1015, 2008.

A. Mejias and O. Ramilo, New options in the treatment of respiratory syncytial virus disease, J Infect, vol.71, issue.1, pp.80-87, 2015.

, Novel therapies and vaccines against the human respiratory syncytial virus, Expert Opin. Investig. Drugs, issue.12, p.24, 2015.

K. Ventre and A. Randolph, WITHDRAWN: ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children, Cochrane Database Syst Rev, vol.5, p.181, 2010.

B. J. Law, E. E. Wang, and N. Macdonald, Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database, Pediatrics, vol.99, issue.3, p.7, 1997.

J. L. Douglas, M. L. Panis, and E. Ho, Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein, J Virol, vol.77, issue.9, pp.5054-5064, 2003.

J. P. Devincenzo, R. J. Whitley, and R. L. Mackman, Oral GS-5806 activity in a respiratory syncytial virus challenge study, N Engl J Med, vol.371, issue.8, pp.711-722, 2014.

S. Bond, A. G. Draffan, and J. E. Fenner, 1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a] isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate, Bioorg Med Chem Lett, vol.25, issue.4, pp.976-981, 2015.

P. R. Wyde, S. Laquerre, and S. N. Chetty, Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol, Antiviral Res, vol.68, issue.1, pp.18-26, 2005.

J. Chapman, E. Abbott, and D. G. Alber, RSV604, a novel inhibitor of respiratory syncytial virus replication, Antimicrob Agents Chemother, vol.51, issue.9, pp.3346-3353, 2007.

C. L. Tiong-yip, L. Aschenbrenner, and K. D. Johnson, Characterization of a respiratory syncytial virus L protein inhibitor, Antimicrob Agents Chemother, vol.58, issue.7, pp.3867-3873, 2014.

J. Devincenzo, J. E. Cehelsky, and R. Alvarez, Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)

, Antiviral Res, vol.77, issue.3, pp.225-231, 2008.

, * Phase 1 study of a siRNA against hRSV nucleocapsid protein mRNA

Z. Sun, Y. Pan, and S. Jiang, Respiratory syncytial virus entry inhibitors targeting the F protein, Viruses, vol.5, issue.1, pp.211-225, 2013.

S. L. Noton, K. Nagendra, and E. F. Dunn, Respiratory syncytial virus inhibitor AZ-27 differentially inhibits different polymerase activities at the promoter, J Virol, vol.89, issue.15, pp.7786-7798, 2015.

L. Cass, K. Ito, and C. Charron, RV568, a narrow spectrum kinase inhibitor (NSKI), inhibits virus induced nasal interleukin-8 (IL8) in the human viral challenge model where healthy adult male volunteers were experimentally inoculated with live respiratory syncytial virus, Eur Res J, vol.42, p.1970, 2013.

J. Devincenzo, R. Lambkin-williams, and T. Wilkinson, A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus, Proc Natl Acad Sci USA, vol.107, pp.8800-8805, 2010.

J. V. Williams, J. H. Weitkamp, and D. L. Blum, The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations, Mol Immunol, vol.47, issue.2-3, pp.407-414, 2009.

T. Rothoeft, K. Fischer, and S. Zawatzki, Differential response of human naive and memory/effector T cells to dendritic cells infected by respiratory syncytial virus, Clin Exp Immunol, vol.150, issue.2, pp.263-273, 2007.

A. Marchant, T. Goetghebuer, and M. O. Ota, Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination, J Immunol, vol.163, issue.4, pp.2249-2255, 1999.

S. Basha, N. Surendran, and M. Pichichero, Immune responses in neonates, Exp Rev Clin Immunol, vol.10, issue.9, pp.1171-1184, 2014.

J. A. Espinoza, K. Bohmwald, and P. F. Cespedes, Impaired learning resulting from respiratory syncytial virus infection, Proc Natl Acad Sci USA, vol.110, issue.22, pp.9112-9117, 2013.

J. E. Coe and G. A. Prince, Definition of cotton rat immunoglobulins: sigmodon species differ in expression of IgG isotypes and production of respiratory syncytial virus antibody, Immunology, vol.88, issue.3, pp.323-330, 1996.